Can AI unravel the mysteries of human biology? Could it help design specialty treatments and cures for disease? Geoffrey von Maltzahn and his team at Generate:Biomedicines are bullish on both counts. AI has greatly accelerated progress in genome engineering, bioengineering and nanotechnology and they are getting closer to developing tailored therapeutics. “Six years ago, this was a crazy idea,” he says. “We’re now convinced that 100 percent of protein therapeutics are going to get created this way.” In this special episode of Solve for X, host Manula Selvarajah sits down with von Maltzahn to talk about where the science is now and where it is headed.

Featured in this episode:

Geoffrey von Maltzahn, general partner of Flagship Pioneering, is an inventor and entrepreneur who works at the intersection of biology and artificial intelligence, a specialization that makes him a world-renowned leader in generative biology.

Further reading:

• How generative biology can wipe out our most devastating diseases — for good
• How technology is tackling questions that confound modern medicine
• How we can deliver a better tomorrow through generative biology
• The frontiers of generative biology | MaRS Impact Health 2024

Subscribe to Solve for X: Innovations to Change the World here. And below, find a transcript to “Cracking the code: How generative biology could transform medicine.” This interview was recorded at MaRS Impact Health in June 2024.

Solve for X is brought to you by MaRS, North America’s largest urban innovation hub and a registered charity. MaRS supports startups and accelerates the adoption of high-impact solutions to some of the world’s biggest challenges. For more information, visit marsdd.com.